appetite

Appendicitis: Evolving Tools to Diagnose a Classic Disease

...ic symptoms of abdominal pain, nausea, and loss of appetite have minimal if any predictive value for appendicitis versus other abdominal conditions. Clinicians fail to appreciate appendicitis on presentation in 25-30% of children. Uncertainty often remains even after physical exam. The classic finding of r...

Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival

...eripheral neuropathy(39%), thrombocytopenia (36%), appetite decrease, including reportsof anorexia (36%), pyrexia (34%), vomiting (33%) and anemia (29%).Twenty percent of patients reported at least one episode of grade 4toxicity; the most common grade 4 toxicities were thrombocytopenia(5%) and neutropenia (3%...

Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma

...eripheral neuropathy(39%), thrombocytopenia (36%), appetite decrease, including reportsof anorexia (36%), pyrexia (34%), vomiting (33%) and anemia (29%).Twenty percent of patients reported at least one episode of grade 4toxicity; the most common grade 4 toxicities were thrombocytopenia(5%) and neutropenia (3%...

Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients

...eripheral neuropathy(39%), thrombocytopenia (36%), appetite decrease, including reportsof anorexia (36%), pyrexia (34%), vomiting (33%) and anemia (29%).Twenty percent of patients reported at least one episode of grade 4toxicity; the most common grade 4 toxicities were thrombocytopenia(5%) and neutropenia (3%...

Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session

...tudies demonstrating that trodusquemine suppresses appetite andcauses differential weight loss in a mouse mode...nhibiting PTP-1B, MSI-1436 is expected to decrease appetite andnormalize blood sugar. Trodusquemine has overcome selectivityconcerns that other compounds that t...

Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting

...as a key metabolic regulator,is known to stimulate appetite and food consumption and is believedto play a key role in metabolism and energy storage. A naturallyoccurring hormone produced in the stomach, ghrelin is believed toact primarily at the level of the hypothalamus in the brain, whichgoverns metabolism....

Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23

... understanding of how the brain appearsto regulate appetite and energy expenditure, as well as themechanisms that come into play to limit weight loss over time. Eachproduct candidate is designed to act on a specific group of neuronsin the central nervous system with the goal of achieving appetitesuppression a...

Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop

...eripheral neuropathy(39%), thrombocytopenia (36%), appetite decrease, including reportsof anorexia (36%), pyrexia (34%), vomiting (33%) and anemia (29%).Twenty percent of patients reported at least one episode of grade 4toxicity; the most common grade 4 toxicities were thrombocytopenia(5%) and neutropenia (3%...

Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions

...inhibitingPTP-1B, MSI-1436 is expected to decrease appetite and normalizeblood sugar. Trodusquemine has produced consistent, sustainableweight loss in a variety of animal models and appears to overcomemetabolic readjustment, which often limits sustained weight lossduring caloric restriction. In addition, trod...

OREXIGEN Therapeutics Announces Sustained-Release Formulation of Zonisamide Shows Improved Tolerability When Compared to Immediate Release Formulation

... understanding of how the brain appearsto regulate appetite and energy expenditure, as well as themechanisms that come into play to limit weight loss over time. Eachproduct candidate is designed to act on a specific group of neuronsin the central nervous system with the goal of achieving appetitesuppression a...

New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma

...eripheral neuropathy(39%), thrombocytopenia (36%), appetite decrease, including reportsof anorexia (36%), pyrexia (34%), vomiting (33%) and anemia (29%).Twenty percent of patients reported at least one episode of grade 4toxicity; the most common grade 4 toxicities were thrombocytopenia(5%) and neutropenia (3%...

New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder

... -- Loss of interest or pleasure -- Changes in appetite or weight -- Changes in sleeping patterns -- Psychomotor agitation or retardation -- Fatigue or low energy -- Feeling worthless or guilty for no reason -- Difficulty thinking or concentrating -- Thoughts of death or suicide Further...

Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo

... -- Loss of interest or pleasure -- Changes in appetite or weight -- Changes in sleeping patterns -- Psychomotor agitation or retardation -- Fatigue or low energy -- Feeling worthless or guilty for no reason -- Difficulty thinking or concentrating -- Thoughts of death or suicide Further...

Data Suggest Cymbalta Improved Functioning in Patients with Generalized Anxiety Disorder

... dry mouth; somnolence; constipation; insomnia; appetite decreased; hyperhidrosis; libido decreased; vomiting; ejaculation delayed; and erectile dysfunction. Approximately 16 percent of patients taking Cymbalta discontinued treatment due to an adverse event compared to 4 percen...

Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection

...eripheral neuropathy (39%), thrombocytopenia(36%), appetite decrease, including reports of anorexia (36%),pyrexia (34%), vomiting (33%) and anemia (29%). Twenty percent ofpatients reported at least one episode of grade 4 toxicity; themost common grade 4 toxicities were thrombocytopenia (5%) andneutropenia (3%...

Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success

...s not yetfully understood. Data indicate a loss of appetite as well as anincrease in metabolic rate and a loss of fat mass. In addition, ithas been shown that cannabinoid antagonists can prevent drugreinstatement with cocaine, alcohol and nicotine. Sanofi-Aventishad studied rimonabant as an aid to smoking ces...